Table 2.

Patient demographics and baseline characteristics

ParameterMoxetumomab pasudotox (n = 55)
No.%
Age, y
 Median13
 Range1-25
Age category, y
 ≤347
 >3 to ≤122138
 >12 to ≤192138
 >19916
Male sex3156
Race
 White4582
 Black713
 Asian12
 Other24
Ethnicity
 Hispanic1324
 Non-Hispanic4276
Time from diagnosis to study entry, months
 Median29
 Range7-145
ECOG performance status (≥12 y)n = 32
 059
 11527
 2 or 3815
Lansky scale score (<12 y)n = 20
 Normal range1833
 Mild to moderate restriction224
Prior treatment
 Chemotherapy55100
 Transplantation2647
 Radiation therapy1018
 Biologic36
 Other815
  • ECOG, Eastern Cooperative Oncology Group.